Business · 12/10/2017Updated: 10/17/2026 · 1 min read
FDA Announces Draft Guidance for Developing Antiviral Drugs Against Respiratory Syncytial Virus Infection
Summary
The FDA has released a draft guidance to help pharmaceutical companies develop antiviral drugs for the prevention and treatment of RSV infections, a common cause of respiratory illness in infants and vulnerable populations.